Seer Inc. Cl A (SEER) News
Filter SEER News Items
SEER News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SEER News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SEER News From Around the Web
Below are the latest news stories about SEER INC that investors may wish to consider to help them evaluate SEER as an investment opportunity.
Seer to Present at the J.P. Morgan 43rd Annual Healthcare ConferenceREDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 43rd Annual Healthcare Conference in San Francisco, CA. Seer’s management is scheduled to present and participate in a Q&A session on Wednesday, January 15th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time. A live webcast of the session will |
Spotlight On US Penny Stocks For January 2025As 2024 drew to a close, U.S. markets experienced a mixed finish with major indices like the Dow Jones and S&P 500 posting their largest monthly losses in over two years, despite achieving significant gains throughout the year. For investors looking beyond established giants, penny stocks—often representing smaller or newer companies—remain an intriguing investment area due to their potential for growth and value. This article will explore three such U.S. penny stocks that exhibit financial... |
Seer (NASDAQ:SEER) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and diseaseREDWOOD CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it ranked No. 57 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, |
Seer Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsSeer ( NASDAQ:SEER ) Third Quarter 2024 Results Key Financial Results Revenue: US$4.03m (down 3.1% from 3Q 2023). Net... |
Seer to Participate in Upcoming November Investor ConferencesREDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MAFireside chat on Monday, November 11th at 11:30 a.m. Eastern TimeCanaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NYFireside chat on |
Seer Inc (SEER) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...Despite a slight revenue dip, Seer Inc (SEER) focuses on growth through strategic alliances and geographic expansion. |
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue EstimatesSeer (SEER) delivered earnings and revenue surprises of -17.24% and 19.64%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Seer Reports Third Quarter 2024 Financial ResultsGrowing enthusiasm for Proteograph Product Suite with multiple larger orders from government agencies and continued strong interest in STACREDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Achieved revenue of $4.0 million for the third quarter of 2024Entered into a co-marketing |
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher ScientificCollaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biologyREDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a co-marketing and sales agreement with Thermo Fisher Scientific, the world leader in serving science, to jointly promote Seer’s Proteograph™ Product Suite alongside Thermo Scientific O |